In mice intranasally infected with influenza A virus (IAV), followed by treatment with atomized recombinant GM-CSF and re-infection with S. pneumoniae, inhalation of GM-CSF had significant survival benefits against the secondary attack of S. pneumoniae and significantly reduced the incidence of S. pneumoniae bacteremia (88). This evidence concerns the gene CSF2 and infection.